OrthoPediatrics (KIDS) to Release Earnings on Wednesday

OrthoPediatrics (NASDAQ:KIDS) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect OrthoPediatrics to post earnings of ($0.12) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. OrthoPediatrics had a negative net margin of 14.35% and a negative return on equity of 5.44%. The company had revenue of $52.80 million for the quarter, compared to the consensus estimate of $52.40 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $26.59 on Wednesday. OrthoPediatrics has a twelve month low of $23.51 and a twelve month high of $36.23. The company’s 50 day moving average is $28.37 and its 200 day moving average is $29.96. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03. The company has a market cap of $633.61 million, a PE ratio of -27.70 and a beta of 1.17.

Insiders Place Their Bets

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total value of $293,000.00. Following the sale, the general counsel now owns 77,304 shares in the company, valued at approximately $2,265,007.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 31.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KIDS shares. Truist Financial cut their price target on shares of OrthoPediatrics from $34.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, October 14th. JMP Securities reiterated a “market outperform” rating and issued a $50.00 price target on shares of OrthoPediatrics in a report on Friday, September 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research report on Friday, September 13th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.